Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

US STOCKS SNAPSHOT-Wall St pares gains on report of potential coronavirus drug failing trial

Published 23/04/2020, 18:03
US500
-
DJI
-
GILD
-
IXIC
-

April 23 (Reuters) - Wall Street's main indexes pared gains
sharply on Thursday, after a report that Gilead Sciences
experimental coronavirus drug flopped in its first randomized
clinical trial.
The Chinese trial showed that Gilead's GILD.O antiviral,
remdesivir, did not improve patients' condition or reduce the
pathogen's presence in the bloodstream, the Financial Times
reported, citing draft documents published accidentally by the
World Health Organization. At 12:51 a.m. ET the Dow Jones Industrial Average .DJI was
up 68.61 points, or 0.29%, at 23,544.43, the S&P 500 .SPX was
up 7.46 points, or 0.27%, at 2,806.77 and the Nasdaq Composite
.IXIC was up 33.58 points, or 0.40%, at 8,528.96.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.